Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Alterations in Muscle Tone lll

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genotype-phenotype correlation in PRKN-associated Parkinson's disease.

NPJ Parkinson's disease·2024

Same author

Two sample Mendelian Randomisation using an outcome from a multilevel model of disease progression.

European journal of epidemiology·2024

Same author

Addressing Comorbidities in People with Parkinson's Disease: Considerations From An Expert Panel.

Journal of Parkinson's disease·2024

Same author

Genome-wide Analysis of Motor Progression in Parkinson Disease.

Neurology. Genetics·2023

Same author

Identification of a possible proteomic biomarker in Parkinson's disease: discovery and replication in blood, brain and cerebrospinal fluid.

Brain communications·2023

Same author

The Impact of Type 2 Diabetes in Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2022

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Therapy adherence issues in Parkinson's disease.

Donald Grosset¹,

¹Institute of Neurological Sciences, Glasgow, Scotland, UK. d.grosset@clinmed.gla.ac.uk

Journal of the Neurological Sciences

|October 2, 2009

Summary

Suboptimal adherence to dopamine replacement therapy is a key factor in variable treatment responses for Parkinson's disease (PD) patients. Understanding compliance issues is crucial for improving symptomatic control and managing dopaminergic side effects.

Related Experiment Videos

Last Updated: Jun 19, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Area of Science:

Neurology
Pharmacology

Background:

Dopamine replacement therapy (DRT) is a cornerstone in managing degenerative parkinsonism.
Patient response to DRT often varies significantly, with multiple contributing factors.

Observation:

Sub-optimal therapy compliance, including under- and overuse of medication, is an under-recognized cause of variable DRT response.
Poor adherence can lead to inadequate symptom control or dopaminergic excess syndromes.

Findings:

Studies reveal significant rates of non-adherence in Parkinson's disease (PD) patients.
Factors influencing compliance are complex and multifactorial.
Deviations from prescribed regimens can result in adverse clinical outcomes.

Implications:

Addressing therapy compliance is essential for optimizing DRT effectiveness in PD.
Improved patient education and monitoring strategies may enhance adherence.
Recognizing compliance issues can help prevent or manage complications of PD treatment.